Galmed Pharmaceuticals Ltd. (GLMD)
4.05
-0.26
(-5.92%)
USD |
NASDAQ |
Aug 24, 16:00
4.02
-0.03
(-0.74%)
After-Hours: 20:00
Galmed Pharmaceuticals EPS Diluted (Quarterly) : -2.318 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -2.318 |
| December 31, 2025 | -5.856 |
| September 30, 2025 | -2.772 |
| June 30, 2025 | -5.056 |
| March 31, 2025 | -4.963 |
| December 31, 2024 | -15.42 |
| September 30, 2024 | -18.46 |
| June 30, 2024 | -17.07 |
| March 31, 2024 | -22.42 |
| December 31, 2023 | -38.36 |
| September 30, 2023 | -22.64 |
| June 30, 2023 | -91.02 |
| March 31, 2023 | -104.56 |
| December 31, 2022 | -150.78 |
| September 30, 2022 | -305.84 |
| June 30, 2022 | -214.32 |
| March 31, 2022 | -352.58 |
| December 31, 2021 | -427.72 |
| September 30, 2021 | -442.84 |
| June 30, 2021 | -482.00 |
| March 31, 2021 | -548.61 |
| December 31, 2020 | -693.94 |
| September 30, 2020 | -467.51 |
| June 30, 2020 | -376.19 |
| March 31, 2020 | -412.79 |
| Date | Value |
|---|---|
| December 31, 2019 | -564.44 |
| September 30, 2019 | -307.73 |
| June 30, 2019 | -284.26 |
| March 31, 2019 | -238.49 |
| December 31, 2018 | -253.90 |
| September 30, 2018 | -65.91 |
| June 30, 2018 | -244.80 |
| March 31, 2018 | -244.80 |
| December 31, 2017 | -388.80 |
| September 30, 2017 | -331.20 |
| June 30, 2017 | -316.80 |
| March 31, 2017 | -374.40 |
| December 31, 2016 | -576.00 |
| September 30, 2016 | -489.60 |
| June 30, 2016 | -561.60 |
| March 31, 2016 | -518.40 |
| December 31, 2015 | -417.60 |
| September 30, 2015 | -331.20 |
| June 30, 2015 | -305.37 |
| March 31, 2015 | -316.80 |
| December 31, 2014 | -256.72 |
| September 30, 2014 | -415.90 |
| June 30, 2014 | -227.92 |
| March 31, 2014 | -368.93 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| BioLineRx Ltd. | -0.5804 |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 0.1605 |
| Can-Fite BioPharma Ltd. | -- |
| Revium Recovery, Inc. | -0.0096 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.91M |
| Total Expenses (Quarterly) | 1.91M |
| Enterprise Value | -12.23M |
| Earnings Yield | -395.1% |
| Normalized Earnings Yield | -336.04 |